Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Ken Griffin Boosts AbbVie Stake 547% as Dividend King Yields 2.8%
- Citadel's significant increase in AbbVie highlights the appeal of the company's dividend yield (2.8%) and its track record as a Dividend King. - Investors seeking income and dividend growth may find AbbVie's sustained dividend increases and expanding immunology portfolio attractive.
Based on reporting from yahoo-tickers-tape-movers.
Hedge fund manager Ken Griffin significantly expanded his position in healthcare giant AbbVie (ABBV), increasing his stake by 547%. This move underscores interest in AbbVie's strong dividend yield of approximately 2.8% and its consistent history of dividend growth, a trait that has earned it 'Dividend King' status.
Market context for this story
As of: PremarketLoading quotes…
Informational only — not investment advice. Full markets →
$AD
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/AD and related $ABBV. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
**Implied Volatility / Movement:** N/A Hedge fund manager Ken Griffin's Citadel fund saw a 14% rise in July, with a notable expansion in his exposure to AbbVie (ABBV). Griffin increased his holdings in the healthcare company by 547%, building on a position he has held since 2013. AbbVie currently offers a dividend yield of about 2.8%, having recently increased its quarterly payout by 5.5%. The company boasts a 53-year streak of dividend increases, counting its time as a subsidiary of Abbott Laboratories (ABT).
AbbVie has grown its dividend by over 330% since its 2013 spinoff. The company's strategy includes potential new therapies, such as the acquisition of Apogee Therapeutics (APGE) for its atopic dermatitis candidate, aiming to diversify beyond established drugs like Humira. This strategic acquisition, though adding debt, is seen as a move to secure future growth in a substantial market.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
- Citadel's significant increase in AbbVie highlights the appeal of the
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 19, 2026 at 7:45 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
dividend income and healthcare growth
A famous billionaire investor just bought a huge amount of stock in a major healthcare company known for paying steady cash rewards to its shareholders. People care because reliable dividend-paying companies become very popular when investors look for safe ways to make money.
What changed
Ken Griffin's Citadel increased its holdings in AbbVie by 547%, signaling strong institutional backing for the pharmaceutical firm's income and growth strategy.
Who wins / who loses
Dividend-focused pharmaceutical giants and income-seeking investors benefit, while companies facing patent cliffs without strong pipelines lag.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $ABBVBuild slowly — only if it fits your plan
Major hedge funds are buying this stock because it pays reliable cash rewards and has a long history of increasing those payments.
View $ABBV chart → · End-of-day delayed data
Peer
- $ABTWatch — track, don’t rush
The company that AbbVie originally split from also has a great track record of paying steady cash to investors.
View $ABT chart → · End-of-day delayed data
Second-order
- $APGEWatch — track, don’t rush
Smaller drug companies that get bought out by giants like AbbVie can see sudden spikes in value.
View $APGE chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Covered-call income (only if you already own shares) · Level: intermediate
Beginners should stick to just owning the stock for the cash dividend and skip options until they understand how to generate extra income safely.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Look into other Dividend Kings in the consumer staples or healthcare sectors for steady portfolio income.
What would break this thesis
- Major pipeline drug failures or unexpected patent cliff losses that threaten AbbVie's ability to maintain its dividend growth streak.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).